Envelope protein p54 Antibody

What is the structural composition of ASFV p54 protein?

P54 (encoded by the E183L gene) is a 25 kDa structural type II transmembrane protein of ASFV with an isoelectric point of approximately 6.5. It contains a membrane-spanning domain near its N-terminus and functions as a cargo-binding protein. P54 forms disulfide-linked homodimers through its unique luminal cysteine in both infected cells and in vitro conditions. The protein is essential for virus viability, playing crucial roles in virus morphogenesis, envelope precursor recruitment, and viral infection processes .

Why is p54 protein an ideal target for ASFV antibody detection?

P54 protein serves as an excellent serological target for ASFV detection for several reasons: (1) it's highly immunogenic, eliciting antibody responses as early as 10 days post-infection that persist for several weeks; (2) it demonstrates high conservation across ASFV isolates; (3) antibody detection using recombinant p54 protein shows excellent sensitivity (98%) and specificity (97%) compared to OIE-ELISA standards; and (4) it can be successfully expressed in prokaryotic systems as a soluble protein, facilitating easier production of diagnostic reagents .

What are the key antigenic regions of p54 protein?

Bioinformatic analysis and experimental validation have identified multiple immunogenic epitopes in the p54 protein. The most significant antigenic regions include amino acid positions A23-29, A36-45, A72-94, A114-120, and A137-150. Among these, the A36-45 region shows particularly strong reactivity with monoclonal antibodies, with the sequence 37DIQFINPY44 containing essential amino acids for antibody binding. These regions demonstrate higher antigenic indices, better hydrophilicity, and surface accessibility, making them ideal targets for antibody development .

What are the most effective expression systems for producing recombinant p54 protein?

The most successful approach for p54 expression involves using prokaryotic systems with E. coli BL21(DE3) cells. The protein is typically expressed without its transmembrane domain to enhance solubility. Common expression vectors include pET-28a, pET-21a, and pMAL-c5x. For optimal soluble expression, researchers should:

• Exclude the predicted transmembrane domain from the construct

• Use induction with IPTG at lower temperatures (16-25°C)

• Express as a fusion protein with tags like 6×His or MBP

• Optimize codon usage for E. coli expression

This approach yields soluble recombinant p54 protein with molecular weights ranging from 17 kDa (for the core protein) to 65 kDa (for fusion constructs), depending on the expression system and tags used .

What purification strategies yield the highest quality p54 recombinant protein for immunization?

For generating high-quality p54 protein suitable for immunization, a multi-step purification approach is recommended:

• Initial capture using affinity chromatography (Ni-NTA for His-tagged constructs or amylose resin for MBP fusions)

• Secondary polishing via gel filtration to remove protein aggregates and contaminants

• Buffer exchange to PBS using dialysis or desalting columns

• Concentration determination using Bradford or BCA assays

• Verification of purity using SDS-PAGE and Western blot with anti-His antibodies

This protocol consistently yields protein of >90% purity suitable for animal immunization and antibody production .

What is the optimal immunization protocol for generating anti-p54 monoclonal antibodies?

Based on successful protocols documented in multiple studies, the recommended immunization schedule for BALB/c mice is:

• Primary immunization: 100 μg purified recombinant p54 protein emulsified with equal volume of Freund's complete adjuvant

• Booster immunizations: Two additional injections at 2-3 week intervals using the same amount of antigen emulsified with Freund's incomplete adjuvant

• Final boost: Intraperitoneal injection of 100 μg antigen without adjuvant 3-10 days before cell fusion

• Route: Intraperitoneal injection for all immunizations

This protocol consistently generates high antibody titers (>1:10,000) in immunized mice, which can be verified by indirect ELISA before hybridoma generation .

How can researchers effectively screen and characterize anti-p54 monoclonal antibodies?

A comprehensive characterization workflow includes:

• Initial screening of hybridoma supernatants by indirect ELISA using recombinant p54 protein

• Subcloning positive clones by limiting dilution (at least three rounds)

• Isotype determination using commercial mouse Ig isotyping kits

• Specificity verification through:

  • Western blot analysis against recombinant protein and ASFV-infected cell lysates

  • Immunofluorescence assay on transfected cells expressing p54 and ASFV-infected cells

• Epitope mapping using truncated protein fragments or peptide arrays

• Cross-reactivity testing against different ASFV isolates/genotypes

Most successful anti-p54 mAbs generated have been IgG1 isotype with kappa light chains, recognizing conformational and linear epitopes .

How can anti-p54 monoclonal antibodies be optimized for competitive ELISA development?

To develop a high-performance competitive ELISA using anti-p54 mAbs:

• Select mAbs with high affinity and specificity through preliminary screening

• Determine optimal coating concentration of recombinant p54 protein (typically 0.2 μg/well)

• Establish appropriate serum and mAb dilutions through checkerboard titration

• Optimize incubation times and temperatures (typically 30-60 minutes at 37°C)

• Determine cut-off values using known positive and negative samples

• Calculate percent inhibition using the formula: PI (%) = [(OD mAb only - OD sample)/(OD mAb only)] × 100

• Validate assay parameters:

  • Analytical sensitivity and specificity

  • Reproducibility (CV <10%)

  • Cross-reactivity with other swine pathogens (PRV, PRRSV, CSFV, PCV2, SVA)

  • Agreement with reference methods (>95% concordance)

This approach has yielded competitive ELISAs with >96% agreement with commercial tests and kappa values >0.9, indicating excellent diagnostic performance .

What are the key considerations for epitope mapping of anti-p54 monoclonal antibodies?

For comprehensive epitope mapping of anti-p54 mAbs:

• Generate a systematic set of truncated p54 fragments or overlapping peptides covering the entire protein sequence

• Express truncated fragments as GST fusion proteins or synthesize peptides directly

• Screen fragments/peptides against mAbs using Western blot or ELISA

• For promising regions, create fine mapping peptides with single amino acid substitutions or deletions

• Verify critical binding residues through site-directed mutagenesis

• Analyze epitope conservation across different ASFV isolates by sequence alignment

• Perform structural modeling to predict epitope accessibility on the native protein

This approach has successfully identified the minimum essential amino acid sequence 37DIQFINPY44 within the A36-45 region as a key epitope, which shows conservation across ASFV genotypes .

How can researchers assess the functionality of anti-p54 antibodies in blocking virus attachment?

To evaluate the virus-neutralizing capacity of anti-p54 antibodies:

• Prepare purified IgG from hybridoma supernatants using protein A/G affinity columns

• Pre-incubate ASFV particles with varying concentrations of anti-p54 mAbs

• Inoculate susceptible cells (PAM cells) with antibody-treated virus

• After appropriate incubation time, assess:

  • Virus attachment by immunofluorescence with anti-p72 antibodies

  • Virus entry by detecting early viral proteins

  • Virus replication by quantifying viral genome copies (qPCR)

  • Cytopathic effect by microscopic examination

• Include isotype-matched control antibodies as negative controls

• Calculate percent inhibition compared to untreated virus controls

This approach helps determine whether the antibodies specifically block the p54-mediated virus attachment to susceptible cells, a critical function documented in previous studies .

How does p54 contribute to ASFV morphogenesis and assembly?

P54 plays multiple essential roles in ASFV morphogenesis:

• Membrane recruitment: P54 is critical for recruiting and transforming endoplasmic reticulum (ER) membranes into viral envelope precursors

• Protein targeting: As a type I membrane-anchored protein, p54 naturally localizes to ER membranes even when expressed alone in transfected cells

• Viral factory formation: In the absence of p54 (demonstrated using conditional mutants), virus morphogenesis arrests at a very early stage before the formation of precursor membranes

• Structural organization: Without p54, aberrant "zipper-like" structures formed by unprocessed core polyproteins pp220 and pp62 accumulate in association with ER cisternae

• Viral transport: P54 binds to dynein light chain 8 (DLC8) through a short peptide (149-161 aa) near its C-terminus, facilitating microtubule-mediated transport of viral particles

These functions make p54 indispensable for the proper assembly and morphogenesis of ASFV particles .

How can researchers investigate p54's interaction with cellular components during infection?

To study p54's interactions with host cell components:

• Co-immunoprecipitation assays using anti-p54 antibodies followed by mass spectrometry

• Yeast two-hybrid screening to identify direct protein-protein interactions

• Proximity labeling approaches (BioID, APEX) with p54 as the bait protein

• Fluorescence microscopy to track co-localization with cellular structures:

  • Express p54-fluorescent protein fusions in cells

  • Perform dual immunofluorescence with anti-p54 and antibodies against cellular markers

• Mutational analysis of p54 to identify domains important for specific interactions

• Live-cell imaging to track p54 dynamics during infection

• Electron microscopy with immunogold labeling to visualize p54 localization at ultrastructural level

These approaches have revealed p54's interactions with components of the cytoskeleton, particularly its documented binding to dynein light chain 8, which facilitates transport of viral particles along microtubules .

What strategies can overcome expression difficulties with full-length recombinant p54 protein?

When facing challenges with recombinant p54 expression:

• For insolubility issues:

  • Remove the N-terminal transmembrane domain (typically amino acids 1-53)

  • Use fusion partners that enhance solubility (MBP, GST, SUMO)

  • Lower induction temperature (16°C) and IPTG concentration (0.1-0.5 mM)

  • Try auto-induction media instead of IPTG induction

  • Consider codon optimization for E. coli expression

• For poor yield:

  • Test different E. coli strains (BL21, Rosetta, Arctic Express)

  • Optimize growth media (2XYT or TB instead of LB)

  • Extend induction time at lower temperatures

  • Consider eukaryotic expression systems for full-length protein

• For protein degradation:

  • Add protease inhibitors during purification

  • Reduce purification time with optimized protocols

  • Store protein with glycerol (20-50%) at -20°C or -80°C

  • Use freshly purified protein for immunization

These approaches have successfully addressed common challenges in producing high-quality recombinant p54 suitable for antibody production .

How can researchers address cross-reactivity issues in serological assays using anti-p54 antibodies?

To minimize cross-reactivity in p54-based serological assays:

• For antibody production:

  • Use highly purified recombinant p54 protein for immunization

  • Select hybridoma clones based on specificity testing against multiple antigens

  • Purify monoclonal antibodies using protein A/G chromatography

• For assay development:

  • Include blocking steps with 1-5% BSA or milk proteins

  • Test and optimize serum dilutions (typically 1:10 to 1:40)

  • Incorporate known negative controls from diverse sources

  • Test against related swine pathogens (PRV, PRRSV, CSFV, PCV2, SVA)

• For result interpretation:

  • Establish clear cut-off values based on ROC curve analysis

  • Calculate percent inhibition values for competitive assays

  • Consider parallel testing with alternative assays for confirmation

These approaches have yielded p54-based competitive ELISAs with no cross-reactivity against common swine pathogens while maintaining high diagnostic sensitivity and specificity .

How might epitope-specific anti-p54 antibodies contribute to next-generation ASFV vaccines?

Anti-p54 epitope-specific antibodies could advance ASFV vaccine development through:

• Identification of protective epitopes:

  • Map epitopes recognized by neutralizing antibodies

  • Determine conservation of these epitopes across ASFV genotypes

  • Correlate epitope-specific antibody responses with protection

• Rational vaccine design:

  • Incorporate identified protective epitopes in subunit or vectored vaccines

  • Design multi-epitope constructs combining p54 epitopes with other ASFV immunogens

  • Create chimeric proteins displaying multiple copies of protective epitopes

• Immunomonitoring applications:

  • Develop epitope-specific antibody assays to measure vaccine responses

  • Differentiate infected from vaccinated animals (DIVA) using epitope-based assays

  • Track antibody affinity maturation following vaccination

• Protective mechanism studies:

  • Investigate how anti-p54 antibodies interfere with virus attachment

  • Determine whether they block dynein binding and intracellular transport

  • Assess their role in complement activation or antibody-dependent cellular cytotoxicity

These approaches could overcome current limitations in ASFV vaccine development by targeting functionally critical and conserved epitopes .

What advanced imaging techniques can reveal about p54 dynamics during ASFV infection?

Advanced imaging approaches to study p54 dynamics include:

• Super-resolution microscopy:

  • STED (Stimulated Emission Depletion) microscopy to visualize p54 distribution at ~20nm resolution

  • STORM/PALM for single-molecule localization of p54 in infected cells

  • SIM (Structured Illumination Microscopy) for 3D visualization of p54 in viral factories

• Live-cell imaging:

  • FRAP (Fluorescence Recovery After Photobleaching) to measure p54 mobility

  • Single-particle tracking of fluorescently-labeled virions to follow p54-mediated transport

  • FRET/FLIM to detect p54 interactions with host proteins in real-time

• Correlative light and electron microscopy (CLEM):

  • Combine fluorescence imaging of p54 with ultrastructural analysis

  • Immunogold EM to precisely localize p54 within viral assembly sites

  • Cryo-electron tomography to visualize 3D architecture of p54-containing structures

• Advanced labeling strategies:

  • Split-GFP complementation to detect p54 oligomerization

  • Click chemistry with non-canonical amino acids for pulse-chase experiments

  • Proximity labeling (BioID, APEX) to map p54's molecular neighborhood during infection

These techniques would provide unprecedented insights into p54's dynamic behavior during the ASFV replication cycle, potentially revealing new targets for therapeutic intervention .